drugset / Trial / NCT03126461
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
SequentialOpen-labelTreatment
Summary
A one-arm, single center phase 2 trial of SAbR plus ipilimumab plus nivolumab in advanced metastatic melanoma patients
Timeline
- Start
- 2018-03-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “the project was never initiated and no participants were enrolled, it was closed permanently”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |